Ilumya (tildrakizumab-asmn) has been made available by Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Ilumya, an interleukin-23 antagonist, acts by selectively binding to the p19 subunit of IL-23 and inhibiting its interaction with the IL-23 receptor, blocking the release of pro-inflammatory cytokines and chemokines.
“Ilumya offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,” said Abhay Gandhi, Chief Executive Officer, Sun Pharma, North America. “We understand the importance of patient and physician choice, and are committed to making Ilumya among the most cost-effective treatments on the market today.” Analyses presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2018 meeting showed that compared with non-targeted treatments like apremilast, Ilumya was found to be the most cost-effective; results also demonstrated that Ilumya was more cost-effective than other biologic therapies indicated for plaque psoriasis.
Ilumya is supplied as a 100mg/mL strength solution for subcutaneous injection in single-dose prefilled syringes. Treatment should only be administered by a healthcare provider. Prior to initiating therapy, patients should be evaluated for tuberculosis infection. The most common adverse reactions associated with Ilumya include upper respiratory infections, injection site reactions, and diarrhea.
For more information visit Ilumya.com.
This article originally appeared on MPR